Fish oil supplementation ameliorates fructose-induced hypertriglyceridemia and insulin resistance in adult male rhesus macaques

Journal of Nutrition

Volumn 144, Issue 1, 2014, Pages 5-11

  Bremer, Andrew A ^a   Stanhope, Kimber L ^b   Graham, James L ^b   Cummings, Bethany P ^b   Ampah, Steve B ^a   Saville, Benjamin R ^a   Havel, Peter J ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; FISH OIL; FRUCTOSE; GLUCOSE; INSULIN; LEPTIN;

ANIMAL EXPERIMENT; ARTICLE; CARDIOMETABOLIC RISK; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIET RESTRICTION; DIET SUPPLEMENTATION; DIETARY INTAKE; FAT MASS; GLUCOSE METABOLISM; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; LEAN BODY WEIGHT; MALE; NONHUMAN; RHESUS MONKEY; SUPPLEMENTATION;

EID: 84890898955     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.113.178061     Document Type: Article

References (52)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-28.
2. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28:629-36.
3. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH. The metabolic syndrome. Endocr Rev. 2008;29:777-822.
4. Havel PJ. Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev. 2005;63: 133-57.
5. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
6. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essen- tial hypertension, and cardiovascular disease. J Clin Endocrinol Metab. 2003;88:2399-403.
7. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am. 2004;33:283-303.
8. Reaven GM. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulinresistant individuals. Endocrinol Metab Clin North Am. 2005;34:49-62.
9. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58:2047-67.
10. Mozaffarian D, Wu JH. (n-3) Fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr. 2012;142 Suppl:614S-25S.
11. Siriwardhana N, Kalupahana NS, Moustaid-Moussa N. Health benefits of n-3 polyunsaturated fatty acids: eicosapentaenoic acid and docosahexaenoic acid. Adv Food Nutr Res. 2012;65:211-22.
12. Harris WS. n-3 Fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids. 1996;31:243-52.
13. Harris WS. N-3 Fatty acids and serum lipoproteins: animal studies. Am J Clin Nutr. 1997;65 Suppl:1611S-6S.
14. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17:387-93.
15. Kalupahana NS, Claycombe KJ, Moustaid-Moussa N. (n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights. Adv Nutr. 2011;2:304-16.
16. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta- analysis. Curr Atheroscler Rep. 2011;13:474-83.
17. Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS. Fish oil prevents insulin resistance induced by highfat feeding in rats. Science. 1987;237:885-8.
18. González-Périz A, Horrillo R, Ferre N, Gronert K, Dong B, Moran-Salvador E, Titos E, Martinez-Clemente M, Lopez-Parra M, Arroyo V, et al. Obesityinduced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J. 2009;23:1946-57.
19. Kalupahana NS, Claycombe K, Newman SJ, Stewart T, Siriwardhana N, Matthan N, Lichtenstein AH, Moustaid-Moussa N. Eicosapentae- noic acid prevents and reverses insulin resistance in highfat diet- induced obese mice via modulation of adipose tissue inflammation. J Nutr. 2010;140:1915-22.
20. Ghafoorunissa IA, Rajkumar L, Acharya V. Dietary (n-3) long chain polyunsaturated fatty acids prevent sucroseinduced insulin resistance in rats. J Nutr. 2005;135:2634-8.
21. Kabir M, Skurnik G, Naour N, Pechtner V, Meugnier E, Rome S, Quignard-Boulange A, Vidal H, Slama G, Clement K, et al. Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr. 2007;86:1670-9.
22. Rivellese AA, Maffettone A, Iovine C, Di Marino L, Annuzzi G, Mancini M, Riccardi G. Longterm effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertri- glyceridemia. Diabetes Care. 1996;19:1207-13.
23. Hendrich S. (n-3) Fatty acids: clinical trials in people with type 2 diabetes. Adv Nutr. 2010;1:3-7.
24. Cummings BP, Stanhope KL, Graham JL, Griffen SC, Havel PJ. Supplementation with EPA or fish oil for 11 months lowers circulating lipids, but does not delay the onset of diabetes in UC Davistype 2 diabetes mellitus rats. Br J Nutr. 2010;104:1628-34.
25. Cummings BP, Digitale EK, Stanhope KL, Graham JL, Baskin DG, Reed BJ, Sweet IR, Griffen SC, Havel PJ. Development and characterization of a novel rat model of type 2 diabetes mellitus: the UC Davis type 2 diabetes mellitus UCD-T2DM rat. Am J Physiol Regul Integr Comp Physiol. 2008;295:R1782-93.
26. Nettleton JA, Katz R. n-3 Longchain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet Assoc. 2005;105:428-40.
27. Bremer AA, Stanhope KL, Graham JL, Cummings BP, Wang W, Saville BR, Havel PJ. Fructosefed rhesus monkeys: a nonhuman primate model of insulin resistance, metabolic syndrome, and type 2 diabetes. Clin Transl Sci. 2011;4:243-52.
28. Ley CJ, Lees B, Stevenson JC. Sex- and menopauseassociated changes in bodyfat distribution. Am J Clin Nutr. 1992;55:950-4.
29. Narita H, Ohkubo F, Yoshida T, Cho F, Yoshikawa Y. Measuring bone mineral content and soft tissue mass in living the cynomolgus monkey. Jikken Dobutsu. 1994;43:261-5.
30. Swarbrick MM, Havel PJ, Levin AA, Bremer AA, Stanhope KL, Butler M, Booten SL, Graham JL, McKay RA, Murray SF, et al. Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides im- proves insulin sensitivity and increases adiponectin concentrations in monkeys. Endocrinology. 2009;150:1670-9.
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta- cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
32. Butler AA, Tam CS, Stanhope KL, Wolfe BM, Ali MR, O'Keeffe M, St-Onge MP, Ravussin E, Havel PJ. Low circulating adropin concen- trations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab. 2012;97:3783-91.
33. Shearer GC, Savinova OV, Harris WS. Fish oilhow does it reduce plasma triglycerides? Biochim Biophys Acta 2012;1821:843-851.
34. Swahn E, von Schenck H, Olsson AG. Omega-3 ethyl ester concentrate decreases total apolipoprotein CIII and increases antithrombin III in postmyocardial infarction patients. Clin Drug Investig. 1998;15: 473-82.
35. Fan C, Liu X, Shen W, Deckelbaum RJ, Qi K. The regulation of leptin, leptin receptor and proopiomelanocortin expression by n-3 PUFAs in dietinduced obese mice is not related to the methylation of their promoters. Nutr Metab (Lond). 2011;8:31.
36. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adiposederived protein. Diabetes. 2001;50:2094-9.
37. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002;51:2968-74.
38. Swarbrick MM, Havel PJ. Physiological, pharmacological, and nutri- tional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord. 2008;6:87-102.
39. Kallen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA. 1996;93:5793-6.
40. Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T. Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab. 2003;21:166-71.
41. Zheng H, Li S, Ma L, Cheng L, Deng C, Chen Z, Xie C, Xiang M, Jiang W, Chen L. A novel agonist of PPAR-gamma based on barbituric acid alleviates the development of nonalcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance. Eur J Pharmacol. 2011;659:244-51.
42. Kratz M, Swarbrick MM, Callahan HS, Matthys CC, Havel PJ, Weigle DS. Effect of dietary n-3 polyunsaturated fatty acids on plasma total and highmolecularweight adiponectin concentrations in overweight to moderately obese men and women. Am J Clin Nutr. 2008;87:347-53.
43. Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, Kousoulas KG, Rogers PM, Kesterson RA, Thearle M, et al. Identification of adropin as a secreted factor linking dietary macronu- trient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8:468-81.
44. Ganesh Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, Culler MD, Mynatt RL, Butler AA. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring). 2012;20:1394-402.
45. Kuang YL, Paulson KE, Lichtenstein AH, Matthan NR, Lamon-Fava S. Docosahexaenoic acid suppresses apolipoprotein A-I gene expression through hepatocyte nuclear factor-3b. Am J Clin Nutr. 2011;94: 594-600.
46. Lee SP, Dart AM, Walker KZ, O'Dea K, Chin-Dusting JP, Skilton MR. Effect of altering dietary n-6:n-3 PUFA ratio on cardiovascular risk measures in patients treated with statins: a pilot study. Br J Nutr. 2012;108:1280-5.
47. Mooijaart SP, Berbee JF, van Heemst D, Havekes LM, de Craen AJ, Slagboom PE, Rensen PC, Westendorp RG. ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med. 2006;3:e176.
48. Blasbalg TL, Hibbeln JR, Ramsden CE, Majchrzak SF, Rawlings RR. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr. 2011;93: 950-62.
49. Harris WS, Von Schacky C. The Omega-3 index: a new risk factor for death from coronary heart disease? Prev Med. 2004;39:212-20.
50. Harris WS. The omega-3 index as a risk factor for coronary heart disease. Am J Clin Nutr. 2008;87:1997S-2002S.
51. Aarsetoey H, Aarsetoey R, Lindner T, Staines H, Harris WS, Nilsen DW. Low levels of the omega-3 index are associated with sudden cardiac arrest and remain stable in survivors in the subacute phase. Lipids. 2011;46:151-61.
52. Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, et al. Consuming fructosesweetened, not glucosesweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009;119:1322-34.